Frontlight ResearchEarly access
CompletedPhase 1
Open-label single dose trial to evaluate pharmacokinetics, safety, and acceptability/palatability of oveporexton in children from 6 years to less than 18 years of age with NT1
Key facts
- Who runs it
- Takeda Development Center Americas Inc.
- Where
- Italy1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 1
- People taking part
- 16 people enrolled
- Started
- 7 Jan 2026
- Ended
- 21 May 2026
- Type of study
- Interventional
- Record updated
- 27 November 2025
Who can take part
- Age
- Up to 17 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (10)Hide the full registry criteria
Who can take part
- The participant has an ICSD-3 or ICSD-3-TR diagnosis of NT1
- Male or female participants aged 6 to 17 years, inclusive, at the time of signing the ICF
- The participant has a body mass index within the range 18 to 30 kg/m2
- The participant is positive for the human leukocyte antigen (HLA) genotype HLA-DQB1*06:02 or results from radioimmunoassay indicate the participant’s CSF OX/hypocretin-1 concentration is <110 pg/mL
- The participant is judged by the investigator to be sufficiently healthy to participate in the trial based on clinical evaluations including laboratory safety tests, medical history, physical examination, 12-lead ECG, and vital sign measurements performed at the screening visit and before the first dose of trial intervention
- Parent or legal guardian – and participants old enough to understand - have expressed a willingness to participate in and complete the trial and signed and dated the ICF after getting acquainted with the participant’s information sheet, prior to beginning protocol-required procedures
Who cannot take part
- Participant is unable to refrain from using excluded medications
- The participant has a positive urine screen result for drugs of abuse and/or positive alcohol test result at screening or at Day -1
- Participant has a known hypersensitivity to any component of the formulation of oveporexton or related compounds
- Participant has a positive pregnancy test result at screening or is breastfeeding
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To determine the plasma pharmacokinetic (PK) parameters of oveporexton in pediatric participants.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Open-label single dose trial to evaluate pharmacokinetics, safety, and acceptability/palatability of oveporexton in children from 6 years to less than 18 years of age with narcolepsy type 1 (NT1)
- Record updated
- 27 November 2025